The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects
Horm Metab Res DOI: 10.1055/a-1825-9641The use of standard procedures for the diagnosis of osteoporosis and assessment
of fracture risk significantly decreased during the COVID-19 pandemic, while the
incidence of fragility fractures was mostly unaltered. Both COVID-19 per se and
its treatments are associated with a negative impact on bone health. Preclinical
models show that mice infected with SARS-CoV2 even without symptoms display loss
of trabecular bone mass two weeks post infection, due to increased numbers of
osteoclasts. Osteoporosis medications do not aggravate the clinical course of
COVID-19, while preclinical data suggests possible beneficial effects of some
therapies. While vitamin D deficiency is clearly associated with a worse
clinical course of COVID-19, evidence of improved patient outcome with vitamin D
supplementation is lacking. Osteoporosis treatment should not be generally
discontinued, and recommendations for substituting therapies are available.
Osteoporosis therapies do not interfere with the efficacy or side-effect
profiles of COVID-19 vaccines and should not be stopped or indefinitely delayed
because of vaccination. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Tsourdi, Elena Hofbauer, Lorenz Rauner, Martina Tags: Review Source Type: research
More News: Covid Vaccine | COVID-19 | Endocrinology | Hormones | Orthopaedics | Osteoporosis | Pandemics | SARS | Vaccines | Vitamin D | Vitamin D Deficiency | Vitamins